This page shows the latest ASH 2020 news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Kite division presented new phase 2 data for its CAR T therapy Yescarta at ASH 2020 in relapsed or refractory high-risk large B-cell lymphoma (LBCL), a potential ... bluebird bio also posted long-term data for its own beta thalassaemia gene
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...